Phenindione


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Thromboembolic disorders
Adult: Initially, 200 mg on day 1 followed by 100 mg on day 2. From day 3, adjust dose according to coagulation tests. Maintenance: 50-150 mg daily (resistant patients may require ≥200 mg daily while sensitive patients may require <50 mg daily).
Elderly: Dosage reduction may be needed.
Renal Impairment
Severe: Contraindicated.
Hepatic Impairment
Severe: Contraindicated.
Chống chỉ định
Hypersensitivity. Significant bleeding, haemorrhagic conditions (e.g. haemorrhagic stroke), bacterial endocarditis, uncontrolled HTN; w/in 48 hr postpartum. Severe renal and hepatic impairment. Pregnancy and lactation. Concomitant use of fibrinolytic agents.
Thận trọng
Patient w/ risk factors for bleeding (e.g. risk of falling, cerebrovascular disease, serious heart disease, anaemia, malignancy, trauma); genetic variability in relation to VKORC1, recent ischaemic stroke, previous GI bleeding, active peptic ulcers, hyper- or hypothyroidism, acute illnesses; wt loss/gain, protein C or S deficiency, hyperphosphataemia, hypercalcaemia, hypoalbuminaemia. Patient undergoing surgery. Mild to moderate renal impairment. Elderly.
Phản ứng phụ
Significant: Hypersensitivity reactions (including fever, lymphadenopathy, agranulocytosis, eosinophilia, leukocytosis, pancytopenia, leukaemoid syndrome, diarrhoea, vomiting, jaundice, rash, alopecia, skin necrosis, exfoliative dermatitis, renal damage w/ tubular necrosis, albuminuria), haemorrhage. Rarely, calciphylaxis.
Nervous: Cerebral haemorrhage, cerebral subdural haematoma.
CV: Haemorrhage.
GI: GI haemorrhage, rectal haemorrhage, haematemesis, pancreatitis, dysgeusia, nausea, melaena.
Resp: Haemothorax, epistaxis.
Hepatic: Hepatitis.
Genitourinary: Pink- or orange- coloured urine, haematuria.
Haematologic: Decreased hematocrit, decreased Hb; leucopenia.
Dermatologic: Purpura, blue toe syndrome, ecchymosis, exanthema.
Monitoring Parameters
Regularly monitor prothrombin time and assess the need for therapy.
Quá liều
Symptoms: Spontaneous bruising, haematomas, haematuria, rectal bleeding, haemorrhage into any internal organ. Management: Give activated charcoal if ingestion is recent (w/in 1 hr) and ingested amount is >0.25 mg/kg or more than the patient’s therapeutic dose. If prothrombin time is prolonged w/ no active bleeding, give vit K 0.5-1 mg by slow IV infusion. If w/ active bleeding, give fresh frozen plasma and vit K 1 mg by slow IV infusion. If w/ life threatening haemorrhage, give fresh frozen plasma or factor concentrate.
Tương tác
Risk of haemorrhage w/ antineoplastics. antiplatelets, unfractionated heparins and heparin derivatives, LMWH, NSAIDs, SSRIs, SNRIs, bivalirudin, clofibrate, dipyridamole, eptifibatide, fondaparinux, miconazole, prostacyclin, sulfinpyrazone. May cause potentiated effect w/ ACTH, allopurinol, amiodarone, amitriptyline/nortriptyline, cimetidine, dextropropoxyphene, disulfiram, glucagon, phenformin, propafenone, thyroid compd, tolbutamide, zafirlukast, broad spectrum antibacterials, steroids, OCs. Antagonised effect w/ barbiturates, carbamazepine, griseofulvin, phenytoin. Decreased absorption w/ cholestyramine, sucralfate.
Potentially Fatal: Significantly increased risk of haemorrhage w/ fibrinolytic agents (e.g. streptokinase, alteplase).
Food Interaction
Reduced effects w/ ingestion of food rich in vit K.
Tác dụng
Description: Phenindione is an indanedione anticoagulant. It antagonises the effects of vitamin K and interferes w/ the formation of clotting factors II, VII, IX and X.
Onset: 36-48 hr.
Duration: 48-72 hr.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed from the GI tract. Time to peak plasma concentration: 1-3 hr.
Distribution: Crosses placenta and enters breast milk.
Excretion: Via urine (as metabolites).
Đặc tính

Chemical Structure Image
Phenindione

Source: National Center for Biotechnology Information. PubChem Database. Phenindione, CID=4760, https://pubchem.ncbi.nlm.nih.gov/compound/Phenindione (accessed on Jan. 22, 2020)

Phân loại ATC
B01AA02 - phenindione ; Belongs to the class of vitamin K antagonists. Used in the treatment of thrombosis.
References
Buckingham R (ed). Phenindione. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. ttps://www.medicinescomplete.com. Accessed 17/10/2017.

Dindevan 25 mg Tablets (Mercury Pharma Group Ltd). MHRA. https://products.mhra.gov.uk/. Accessed 23/11/2017.

Joint Formulary Committee. Phenindione. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/10/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Phenindione từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in